Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist.
Authors: Weigand S, Herting F, Maisel D, Nopora A, Voss E, Schaab C, Klammer M, Tebbe A
Cancer Res, 2102;72(17):4329-39.
Species: Mouse
Sample Type: Tissue Homogenates

Stand-Sit Microchip for High-Throughput, Multiplexed Analysis of Single Cancer Cells
Sci Rep, 2016;6(0):32505.
Application: High Throughput Chip Assay
The catalytic subunit of protein phosphatase 2A (PP2Ac) promotes DNA hypomethylation by suppressing the phosphorylated mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)/phosphorylated ERK/DNMT1 protein pathway in T-cells from controls and systemic lupus erythematosus patients.
Authors: Sunahori, Katsue, Nagpal, Kamalpre, Hedrich, Christia, Mizui, Masayuki, Fitzgerald, Lisa M, Tsokos, George C
J Biol Chem, 2013;288(30):21936-44.
Species: Human
Sample Type: Cell Lysate

Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression.
Authors: Zhang Y, Gonzalez RM, Zangar RC
BMC Cancer, 2011;11(0):69.
Species: Human
Sample Type: Cell Lysates

Real-time monitoring of Cisplatin-induced cell death.
Authors: Alborzinia H, Can S, Holenya P, Scholl C, Lederer E, Kitanovic I, Wolfl S
PLoS ONE, 2011;6(5):e19714.
Species: Human
Sample Type: Cell Lysates

Microarray-based kinetic colorimetric detection for quantitative multiplex protein phosphorylation analysis.
Authors: Holenya P, Kitanovic I, Heigwer F, Wolfl S
Proteomics, 2011;11(10):2129-33.
Species: Human
Sample Type: recombinant pERK1

Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models.
Authors: Wang S, Guo P, Wang X, Zhou Q, Gallo JM
Mol. Cancer Ther., 2008;7(2):407-17.
Species: Mouse
Sample Type: Tissue Homogenates

Lipopolysaccharide-activated IL-10-secreting dendritic cells suppress experimental autoimmune uveoretinitis by MHCII-dependent activation of CD62L-expressing regulatory T cells.
Authors: Lau AW, Biester S, Cornall RJ, Forrester JV
J. Immunol., 2008;180(6):3889-99.
Species: Mouse
Sample Type: Cell Lysates

Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration.
Authors: Proost P, Mortier A, Loos T, Vandercappellen J, Gouwy M, Ronsse I, Schutyser E, Put W, Parmentier M, Struyf S, Van Damme J
Blood, 2007;110(1):37-44.
Species: Hamster
Sample Type: Cell Lysates

In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance.
Authors: Aguila B, Coulbault L, Boulouard M, Leveille F, Davis A, Toth G, Borsodi A, Balboni G, Salvadori S, Jauzac P, Allouche S
Br. J. Pharmacol., 2007;152(8):1312-24.
Species: Human
Sample Type: Cell Lysates

ERK1 and ERK2 (also known as MAPK3 and MAPK1) are 44 and 42 kDa Ser/Thr kinases, respectively. They are part of the Ras-Raf-ERK signal transduction cascade often found downstream of growth factor receptor activation. ERK1 and ERK2 were initially isolated and cloned as kinases activated in response to insulin and NGF. They are expressed in most, if not all, mammalian tissues. Dual threonine and tyrosine phosphorylation activate both ERKs, at Thr202/Tyr204 for human ERK1 and Thr185/Tyr187 for human ERK2.

ERK5, also known as Big Mitogen-activated Protein Kinase 1 (BMK1) and MAPK7, is activated by several mechanisms, including receptor tyrosine kinases, G protein-coupled receptors, and osmotic stress. Like ERK1 and ERK2, ERK5 contains the conserved Thr-Glu-Tyr activation motif in its activation loop. Unlike these ERKs, however, ERK5 contains a unique C-terminal domain that regulates its activation and nuclear translocation.